PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents changing 96.69% while RVPH's remains stable. Warren Buffett would analyze the strategic implications of this divergence.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Below half of RVPH's 55238.12%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Higher Other Current Assets Growth compared to RVPH's zero value, indicating worse performance.
94.31%
Below half of RVPH's 55238.12%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.34%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
Below half of RVPH's 100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Higher Total Assets Growth compared to RVPH's zero value, indicating better performance.
-11.61%
Higher Accounts Payable Growth compared to RVPH's zero value, indicating worse performance.
-42.55%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Higher Total Current Liabilities Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
Less than half of RVPH's -100.00%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
Less than half of RVPH's -100.00%. David Dodd sees far fewer liability expansions relative to competitor.
36.01%
Higher Common Stock (Book Value) Growth compared to RVPH's zero value, indicating worse performance.
-2.61%
Both RVPH and the company show zero Retained Earnings Growth.
-6.95%
Less than half of RVPH's 100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
193.87%
≥ 1.5x RVPH's 100.00%. David Dodd sees stronger capital base growth than competitor.
78.33%
Higher Liabilities + Equity Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
-116.79%
Higher Net Debt Growth compared to RVPH's zero value, indicating worse performance.